Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)

Abstract Background Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continuous positive airway pressure (CPAP) is a feasible option that enables a...

Full description

Bibliographic Details
Main Authors: Jonas Tverring, Anna Åkesson, Niklas Nielsen
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Trials
Subjects:
Online Access:https://doi.org/10.1186/s13063-020-04863-5
_version_ 1818647151597584384
author Jonas Tverring
Anna Åkesson
Niklas Nielsen
author_facet Jonas Tverring
Anna Åkesson
Niklas Nielsen
author_sort Jonas Tverring
collection DOAJ
description Abstract Background Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continuous positive airway pressure (CPAP) is a feasible option that enables a higher positive end-expiratory pressure (PEEP) and may theoretically reduce the need for intubation compared to HFNC but direct comparative evidence is lacking. Methods We plan to perform an investigator-initiated, pragmatic, randomised trial at an intermediate-level COVID-19 cohort ward in Helsingborg Hospital, southern Sweden. We have estimated a required sample size of 120 patients randomised 1:1 to HFNC or Helmet CPAP to achieve 90% power to detect superiority at a 0.05 significance level regarding the primary outcome of ventilator free days (VFD) within 28 days using a Mann-Whitney U test. Patient recruitment is planned to being June 2020 and be completed in the first half of 2021. Discussion We hypothesise that the use of Helmet CPAP will reduce the need for invasive mechanical ventilation compared to the use of HFNC without having a negative effect on survival. This could have important implications during the current COVID-19 epidemic. Trial registration ClinicalTrials.gov NCT04395807 . Registered on 20 May 2020
first_indexed 2024-12-17T00:57:59Z
format Article
id doaj.art-58da871347624e709bd692f8669841e6
institution Directory Open Access Journal
issn 1745-6215
language English
last_indexed 2024-12-17T00:57:59Z
publishDate 2020-12-01
publisher BMC
record_format Article
series Trials
spelling doaj.art-58da871347624e709bd692f8669841e62022-12-21T22:09:33ZengBMCTrials1745-62152020-12-0121111010.1186/s13063-020-04863-5Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)Jonas Tverring0Anna Åkesson1Niklas Nielsen2Lunds universitet Medicinska fakultetenLunds universitet Medicinska fakultetenLunds universitet Medicinska fakultetenAbstract Background Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continuous positive airway pressure (CPAP) is a feasible option that enables a higher positive end-expiratory pressure (PEEP) and may theoretically reduce the need for intubation compared to HFNC but direct comparative evidence is lacking. Methods We plan to perform an investigator-initiated, pragmatic, randomised trial at an intermediate-level COVID-19 cohort ward in Helsingborg Hospital, southern Sweden. We have estimated a required sample size of 120 patients randomised 1:1 to HFNC or Helmet CPAP to achieve 90% power to detect superiority at a 0.05 significance level regarding the primary outcome of ventilator free days (VFD) within 28 days using a Mann-Whitney U test. Patient recruitment is planned to being June 2020 and be completed in the first half of 2021. Discussion We hypothesise that the use of Helmet CPAP will reduce the need for invasive mechanical ventilation compared to the use of HFNC without having a negative effect on survival. This could have important implications during the current COVID-19 epidemic. Trial registration ClinicalTrials.gov NCT04395807 . Registered on 20 May 2020https://doi.org/10.1186/s13063-020-04863-5COVID-19Randomised controlled trial protocolHelmet CPAPHFNCVentilator-free days
spellingShingle Jonas Tverring
Anna Åkesson
Niklas Nielsen
Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)
Trials
COVID-19
Randomised controlled trial protocol
Helmet CPAP
HFNC
Ventilator-free days
title Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)
title_full Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)
title_fullStr Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)
title_full_unstemmed Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)
title_short Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)
title_sort helmet continuous positive airway pressure versus high flow nasal cannula in covid 19 a pragmatic randomised clinical trial covid helmet
topic COVID-19
Randomised controlled trial protocol
Helmet CPAP
HFNC
Ventilator-free days
url https://doi.org/10.1186/s13063-020-04863-5
work_keys_str_mv AT jonastverring helmetcontinuouspositiveairwaypressureversushighflownasalcannulaincovid19apragmaticrandomisedclinicaltrialcovidhelmet
AT annaakesson helmetcontinuouspositiveairwaypressureversushighflownasalcannulaincovid19apragmaticrandomisedclinicaltrialcovidhelmet
AT niklasnielsen helmetcontinuouspositiveairwaypressureversushighflownasalcannulaincovid19apragmaticrandomisedclinicaltrialcovidhelmet